Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centhaquine as an Adjuvant for Hypovolemic Shock
NCT05251181Phase 3Not yet recruiting
- Sponsor
- Pharmazz, Inc.
- Start
- Feb 2027
- Primary completion
- Oct 2028
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of centhaquine in hypovolemic shock, sponsored by Pharmazz, Inc. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
centhaquine
03
Conditions
hypovolemic shock
Beyond the preview
Go deeper on NCT05251181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251181.